Invention Grant
- Patent Title: Anti-semaphorin 3A antibody and treatment of Alzheimer's disease and inflammatory immune diseases using same
-
Application No.: US14766062Application Date: 2014-02-06
-
Publication No.: US09879075B2Publication Date: 2018-01-30
- Inventor: Yoshio Goshima , Fumio Nakamura , Naoya Yamashita , Hidetaka Seo , Shuichi Hashimoto , Koji Murakami , Naoki Takahashi , Yukie Sasakura
- Applicant: Yokohama City University , Chiome Bioscience Inc.
- Applicant Address: JP Yokohama-shi, Kanagawa, Tokyo
- Assignee: Yokohama City University and Chiome Bioscience Inc.
- Current Assignee: Yokohama City University and Chiome Bioscience Inc.
- Current Assignee Address: JP Yokohama-shi, Kanagawa, Tokyo
- Agency: Knobbe, Martens, Olson & Bear, LLP
- Priority: JP2013-021309 20130206
- International Application: PCT/JP2014/052758 WO 20140206
- International Announcement: WO2014/123186 WO 20140814
- Main IPC: C07K16/18
- IPC: C07K16/18 ; A61K39/00

Abstract:
The present invention mainly addresses the problem of providing an antibody against semaphorin 3A protein, said antibody enabling effective prevention and/or treatment of a disease, in which Sema 3A protein participates, such as a neurodegenerative disease, autoimmune disease, inflammatory disease, cancer, infectious disease, etc. or disseminated intravascular coagulation syndrome. An anti-Sema 3A antibody comprising CDRs having specific amino acid sequences (SEQ ID NOS: 1-6, 60-62, 64-66, 68-70, 72-74, 76-78, 80-82, 84-86 and 88-90) enables effective prevention and/or treatment of a disease, in which Sema 3A protein participates, such as a neurodegenerative disease, autoimmune disease, inflammatory disease, cancer, infectious disease, etc. or disseminated intravascular coagulation syndrome and, therefore, remarkably ameliorates symptoms associated with such a disease.
Public/Granted literature
Information query